Paper9607110
Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A.
Ill CR and 6 others. Blood Coagul Fibrinolysis, 1997. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. Papers, record 9607110. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9607110
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA, Complementary | Major topic |
| Factor VIII | Major topic |
| Gene Expression Regulation | Major topic |
| Genetic Therapy | Major topic |
| Hemophilia A | Major topic |
| Plasmids | Major topic |
| Carcinoma, Hepatocellular | |
| Humans | |
| Tumor Cells, Cultured |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41511298 | Engineering Liver-Specific Promoters: A Comprehensive Review of Design, Mechanisms, and Clinical Applications in Gene Therapy. | Cells | 2025 | https://conductscience.org/library/papers/41511298 | PubMed |
| 36264632 | Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice. | JCI Insight | 2022 | https://conductscience.org/library/papers/36264632 | PubMed |
| 26653140 | A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver. | Elife | 2015 | https://conductscience.org/library/papers/26653140 | PubMed |
| 26015962 | Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. | Mol Ther Methods Clin Dev | 2014 | https://conductscience.org/library/papers/26015962 | PubMed |
| 22428010 | Impact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transduction. | PLoS One | 2012 | https://conductscience.org/library/papers/22428010 | PubMed |
| 21778099 | Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. | Mol Genet Metab | 2011 | https://conductscience.org/library/papers/21778099 | PubMed |
| 21204705 | Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. | Hum Gene Ther | 2011 | https://conductscience.org/library/papers/21204705 | PubMed |
| 21119624 | Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. | Mol Ther | 2011 | https://conductscience.org/library/papers/21119624 | PubMed |
| 20825281 | Noninvasive repetitive imaging of somatostatin receptor 2 gene transfer with positron emission tomography. | Hum Gene Ther | 2011 | https://conductscience.org/library/papers/20825281 | PubMed |
| 19690517 | Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. | Mol Ther | 2010 | https://conductscience.org/library/papers/19690517 | PubMed |
| 18570932 | Evaluation of gene promoters for liver expression by hydrodynamic gene transfer. | J Surg Res | 2008 | https://conductscience.org/library/papers/18570932 | PubMed |
| 17924344 | Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. | Am J Hum Genet | 2007 | https://conductscience.org/library/papers/17924344 | PubMed |
| 16987711 | Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. | Mol Ther | 2006 | https://conductscience.org/library/papers/16987711 | PubMed |
| 14712305 | Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. | Gene Ther | 2004 | https://conductscience.org/library/papers/14712305 | PubMed |
| 10097136 | Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. | Proc Natl Acad Sci U S A | 1999 | https://conductscience.org/library/papers/10097136 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AMBP | 259 | PubTator's text mining | https://conductscience.org/library/genes/259 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9607110
GET https://conductscience.org/api/papers/v1/9607110/authors